Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 250unit

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 500unit

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 1000unit

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 2000unit

Ηνωμένο Βασίλειο - Αγγλικά - MHRA (Medicines & Healthcare Products Regulatory Agency)

swedish orphan biovitrum ltd - eftrenonacog alfa - powder and solvent for solution for injection - 3000unit

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

swedish orphan biovitrum pty ltd - anakinra, quantity: 100 mg - injection, solution - excipient ingredients: polysorbate 80; sodium citrate dihydrate; water for injections; disodium edetate; sodium chloride - kineret (anakinra) is indicated: -for the treatment of active adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more other disease modifying anti rheumatic drugs (dmards). kineret should be given in combination with methotrexate. - in adult and paediatric patients aged 8 months and older with a body weight of 10 kg or above for the treatment of cryopyrin-associated periodic syndromes (caps) including neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), muckle-wells syndrome (mws), and familial cold autoinflammatory syndrome (fcas). - for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years and above who have failed to respond adequately to non-biological dmards

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - nitisinone - capsule, hard - 2 mg

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - nitisinone - capsule, hard - 5 mg

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - nitisinone - capsule, hard - 10 mg

Σαουδική Αραβία - Αγγλικά - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

swedish orphan biovitrum international ab, sweden - nitisinone - capsule, hard - 20 mg